Integrin Blockers
Integrin Blockers - Related Videos
01:10
Integrins
0 Views •
2023
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM. Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15
Activation of Integrins
0 Views •
2023
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling." In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
02:08
Assessing Muscle Contraction with Neuromuscular Blocker Treatment
0 Views •
2025
This video demonstrates assessing the muscle using cultured motor neurons, Schwann cells, and myotubes, followed by treatment with a neuromuscular blocker to inhibit contraction. Color-coded time-motion graphics show a color-coded time-motion graphic. Red indicates the fastest movement, and blue indicates the slowest.
03:16
Intravenous Delivery of Receptor Blockers to Reduce Brain Edema in a Mouse Model
0 Views •
2025
Source: Zeynalov, E. et. al., Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. J. Vis. Exp. (2016)This video demonstrates the intravenous delivery of an arginine-vasopressin (AVP) receptor antagonist in a mouse model. Transient middle cerebral artery occlusion induces brain edema. An AVP receptor antagonist is administered through a catheter in the left jugular vein, alleviating edema.
01:19
Depolarizing Blockers: Pharmocokinetics
0 Views •
2023
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
FAQs
Two mechanisms are highlighted: an agent can prevent an integrin from binding its ligand, or stabilize a receptor state associated with reduced activation. Either action limits the outside-in signals normally generated after receptor engagement. The downstream consequence is altered regulation of cytoskeletal organization, cell movement, platelet aggregation, and tissue remodeling, depending on the biological context.
Integrins contribute to both disease processes and necessary physiological functions. Blocking them may therefore interrupt pathological inflammation, thrombosis, cancer progression, or vascular disease while also affecting tissue repair or host defense. Development aims to distinguish harmful disease-associated activity from essential integrin functions, so efficacy can be pursued without broadly compromising repair or immune protection.
Reduced activation can modify the signals that organize the cytoskeleton and guide cell movement, including immune-cell trafficking. It can also affect platelet aggregation and tissue remodeling. These outcomes show why integrin inhibition is not limited to adhesion itself: changing receptor signaling can reshape coordinated cellular behaviors relevant to inflammation, clot formation, vascular disease, and cancer progression.
Their clinical relevance spans conditions in which adhesion-linked signaling contributes to inflammation, thrombosis, cancer progression, or vascular disease. Studies may use these agents to test whether interrupting integrin-dependent communication changes disease-associated biology, while therapeutic programs examine whether the same mechanism can produce benefit with acceptable effects on tissue repair and host defense.
Biomarker-guided treatment provides a way to incorporate biological measurements into development rather than treating all disease contexts as equivalent. For integrin-targeted agents, this strategy is relevant because therapeutic goals emphasize disease-selective inhibition. It can help structure research around which biological settings are most suitable for intervention while keeping essential tissue repair and host defense in view.
Evaluation must extend beyond whether an integrin blocker changes disease biology. Development also includes monitoring for resistance, which may limit or alter treatment benefit, and adverse effects that could reflect interference with essential integrin functions. Assessing both dimensions is central to deciding whether inhibition is sufficiently disease-selective for clinical use rather than merely mechanistically active.